Cargando…
The three syndromes and six Chinese patent medicine study during the recovery phase of COVID-19
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), first broke out in Wuhan, China, in 2019. SARS-CoV-2 develops many types of mutations (such as B.1.1.7), making diagnosis and treatment challenging. Although we now have a preliminary und...
Autores principales: | An, Xuedong, Duan, Liyun, Zhang, Yue Hong, Jin, De, Zhao, Shenghui, Zhou, Rong Rong, Duan, Yingying, Lian, Fengmei, Tong, Xiaolin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182732/ https://www.ncbi.nlm.nih.gov/pubmed/34099015 http://dx.doi.org/10.1186/s13020-021-00454-x |
Ejemplares similares
-
The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19
por: An, Xuedong, et al.
Publicado: (2021) -
Potential Mechanism Prediction of Herbal Medicine for Pulmonary Fibrosis Associated with SARS-CoV-2 Infection Based on Network Analysis and Molecular Docking
por: Jin, De, et al.
Publicado: (2021) -
Direct and indirect therapeutic effect of traditional Chinese medicine as an add-on for non-proliferative diabetic retinopathy: a systematic review and meta-analysis
por: An, Xuedong, et al.
Publicado: (2020) -
Effect of Chinese Patent Medicines on Ocular Fundus Signs and Vision in Calcium Dobesilate-Treated Persons With Non-Proliferative Diabetic Retinopathy: A Systematic Review and Meta-Analysis
por: Zhang, Yuehong, et al.
Publicado: (2022) -
Efficacy and mechanisms of traditional Chinese medicine for COVID-19: a systematic review
por: Kang, Xiaomin, et al.
Publicado: (2022)